Table 2. ADH (with or without LN) clinicopathological and radiological variables correlation with upgrade.
| Variables | Upgrade | P-value | ||
|---|---|---|---|---|
| Yes (n = 15) | No (n = 85) | |||
| Clinical | ||||
| Age* | 57 (31,75) | 61 (40, 72) | 57 (31, 75) | 0.37 |
| Race | African American (n = 8) | 2 (25.0) | 6 (75.0) | 0.58 |
| Caucasian (n = 89) | 13 (14.6) | 76 (85.4) | ||
| Menopause status | Post (n = 66) | 11 (16.7) | 55 (83.3) | 0.79 |
| Pre (n = 34) | 4 (11.8) | 30 (88.2) | ||
| Hormonal intake | No (n = 41) | 7 (17.1) | 34 (82.9) | 0.55 |
| Yes (n = 51) | 6 (11.8) | 45 (88.2) | ||
| Breast carcinoma history | ||||
| Concurrent ipsilateral | No (n = 68) | 11 (16.2) | 57 (83.8) | 0.8 |
| Yes (n = 32) | 4 (12.5) | 28 (87.5) | ||
| Concurrent contralateral | No (n = 75) | 10 (13.3) | 65 (86.7) | 0.52 |
| Yes (n = 25) | 5 (20.0) | 20 (80.0) | ||
| Past ipsilateral | No (n = 97) | 13 (13.4) | 84 (86.6) | 0.058 |
| Yes (n = 3) | 2 (66.7) | 1 (33.3) | ||
| Past contralateral | No (n = 88) | 14 (15.9) | 74 (84.1) | 0.69 |
| Yes (n = 12) | 1 (8.3) | 11 (91.7) | ||
| Pathology | ||||
| Concurrent FEA | No (n = 90) | 14 (15.6) | 76 (84.4) | 1 |
| Yes (n = 10) | 1 (10.0) | 9 (90.0) | ||
| Concurrent LN | No (n = 86) | 13 (15.1) | 73 (84.9) | 1 |
| Yes (n = 14) | 2 (14.3) | 12 (85.7) | ||
| No. ADH foci* | 1 (1, 11) | 2 (1, 11) | 1 (1, 5) | 0.21 |
| No. cores (total)* | 8 (3, 17) | 8 (5, 12) | 8 (3, 17) | 0.25 |
| No. cores (involved)* | 1 (1, 8) | 2 (1, 8) | 1 (1, 5) | 0.02 |
| Largest ADH size* | 2 (0.5, 8) | 2.1 (0.5, 4.5) | 2 (0.5, 8) | 0.24 |
| Radiology | ||||
| Gauge | 11–14 (n = 34) | 7 (20.6) | 27 (79.4) | 0.38 |
| 9 (n = 66) | 8 (12.1) | 58 (87.9) | ||
| 8–13 (72) | 10 (13.9) | 62 (86.1) | 0.76 | |
| 14 (28) | 5 (35.7) | 23 (64.3) | ||
| MRI reason | Clinical finding (n = 8) | 1 (12.5) | 7 (87.5) | 0.94 |
| Equivocal mammography (n = 3) | 1 (33.3) | 2 (66.7) | ||
| High risk (n = 38) | 5 (13.2) | 33 (86.8) | ||
| Staging (n = 51) | 8 (15.7) | 43 (84.3) | ||
| Mass versus NME | Mass (n = 34) | 7 (20.6) | 27 (79.4) | 0.38 |
| NME (n = 66) | 8 (12.1) | 58 (87.9) | ||
ADH, Atypical ductal hyperplasia; LN, Lobular neoplasia[atypical lobular hyperplasia (ALH) or lobular carcinoma in situ (LCIS)]; FEA, Flat epithelial atypia; NME, Non-mass enhancement.
*
Continuous variables with median and range; all other variables n (%).